TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 16)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 19)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. – 27)

4 PREMIUM INSIGHTS (Page No. – 30)
4.1 BIOFILMS TREATMENT MARKET OVERVIEW
4.2 BIOFILMS TREATMENT MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
4.3 BIOFILMS TREATMENT MARKET SHARE, BY END USER, 2020 VS. 2025
4.4 BIOFILMS TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW (Page No. – 33)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing prevalence of chronic, surgical, and traumatic wounds
5.2.1.1.1 High incidence of obesity
5.2.1.1.2 Growing geriatric population
5.2.1.1.3 Increasing prevalence of diabetes
5.2.1.1.4 Increase in the number of surgical wounds and SSIs
5.2.1.1.5 Increasing number of traumatic wounds
5.2.1.2 Increasing incidence of burn injuries
5.2.2 OPPORTUNITIES
5.2.2.1 Growth potential in emerging economies
5.2.3 CHALLENGES
5.2.3.1 High cost and low adoption rate of advanced wound care products

6 BIOFILMS TREATMENT MARKET, BY PRODUCT (Page No. – 37)
6.1 INTRODUCTION
6.2 DEBRIDEMENT EQUIPMENT
6.2.1 DEVELOPMENT OF NOVEL TECHNOLOGIES TO SUPPORT MARKET GROWTH
6.3 GAUZES AND DRESSINGS
6.3.1 GAUZES AND DRESSINGS ARE DESIGNED TO PREVENT THE OCCURRENCE OF INFECTIONS AFTER DEBRIDEMENT PROCEDURES
6.4 GRAFTS AND MATRICES
6.4.1 GRAFTS AND MATRICES PROMOTE HEALING AND WOUND CLOSURE
6.5 WIPES, PADS, AND LAVAGE SOLUTIONS
6.5.1 LAVAGE SOLUTIONS ARE USED FOR CLEANING WOUNDS DURING HYDRO SURGICAL AND MECHANICAL DEBRIDEMENT PROCEDURES
6.6 GELS, OINTMENTS, AND SPRAYS
6.6.1 THESE PRODUCTS ARE USED TO TREAT BURNS, DIABETIC FOOT ULCERS, AND SURGICAL & TRAUMATIC WOUNDS

7 BIOFILMS TREATMENT MARKET, BY WOUND TYPE (Page No. – 50)
7.1 INTRODUCTION
7.2 SURGICAL AND TRAUMATIC WOUNDS
7.2.1 GROWING VOLUME OF SURGICAL PROCEDURES PERFORMED TO SUPPORT MARKET GROWTH
7.3 DIABETIC FOOT ULCERS
7.3.1 RISING PREVALENCE OF DIABETES IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT
7.4 PRESSURE ULCERS
7.4.1 GERIATRIC POPULATION IS MORE SUSCEPTIBLE TO DEVELOPING PRESSURE ULCERS
7.5 VENOUS LEG ULCERS
7.5.1 INCREASING PREVALENCE OF OBESITY TO SUPPORT MARKET GROWTH
7.6 BURNS & OTHER OPEN WOUNDS
7.6.1 INCIDENCE OF BURN INJURIES IS HIGH IN EMERGING COUNTRIES

8 BIOFILMS TREATMENT MARKET, BY END USER (Page No. – 57)
8.1 INTRODUCTION
8.2 HOSPITALS, ASCS, AND WOUND CARE CENTERS
8.2.1 RISING INCIDENCE OF HOSPITAL-ACQUIRED PRESSURE ULCERS AND INFECTIONS TO SUPPORT MARKET GROWTH
8.3 HOME CARE SETTINGS
8.3.1 RISING PREFERENCE FOR HOME HEALTHCARE IS CONTRIBUTING TO THE GROWTH OF THIS MARKET
8.4 OTHER END USERS

9 BIOFILMS TREATMENT MARKET, BY REGION (Page No. – 61)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.1.1 Rising prevalence of diabetes and favorable reimbursement policies in the country to boost the market growth
9.2.2 CANADA
9.2.2.1 Increasing government support to boost market growth
9.3 EUROPE
9.3.1 UK
9.3.1.1 Increase in R&D activities to propel market growth in the UK
9.3.2 GERMANY
9.3.2.1 Increasing incidence of diabetes will boost the market growth in Germany
9.3.3 RUSSIA
9.3.3.1 Government focus on increasing diabetes awareness will favor market growth in Russia
9.3.4 FRANCE
9.3.4.1 Rising geriatric population to drive the demand for advanced wound care products in the country
9.3.5 ITALY
9.3.5.1 Unfavorable reimbursement scenario for advanced wound care will hinder market growth in Italy
9.3.6 SPAIN
9.3.6.1 Rising geriatric population in the country to support market growth
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 CHINA
9.4.1.1 Increasing incidence of DFUs to support market growth in China
9.4.2 JAPAN
9.4.2.1 Favorable regulations in Japan have boosted product launch and commercialization activity
9.4.3 INDIA
9.4.3.1 High rate of SSIs and growing investments indicate strong opportunities for market growth
9.4.4 AUSTRALIA
9.4.4.1 Increasing initiatives to spread awareness on effective wound care to support market growth
9.4.5 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.1.1 Brazil is the largest market for healthcare in the Latin American region
9.5.2 MEXICO
9.5.2.1 Diabetes is the second-highest cause of mortality in Mexico
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 GROWING PREVALENCE OF DIABETES TO SUPPORT MARKET GROWTH

10 COMPETITIVE LANDSCAPE (Page No. – 101)
10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2019
10.2.1 BIOFILMS TREATMENT MARKET, BY KEY PLAYER
10.2.2 BIOFILMS TREATMENT MARKET FOR HOSPITALS
10.2.3 BIOFILMS TREATMENT MARKET FOR HOME CARE SETTINGS
10.3 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET)
10.4 VENDOR INCLUSION CRITERIA
10.5 VENDOR DIVE
10.5.1 VISIONARY LEADERS
10.5.2 INNOVATORS
10.5.3 DYNAMIC DIFFERENTIATORS
10.5.4 EMERGING COMPANIES
10.6 COMPETITIVE SCENARIO
10.6.1 PRODUCT LAUNCHES & APPROVALS
10.6.2 ACQUISITIONS
10.6.3 COLLABORATIONS & PARTNERSHIPS

11 COMPANY PROFILES (Page No. – 108)
(Business overview, Products offered, Recent developments, SWOT analysis, MNM view)*
11.1 SMITH AND NEPHEW PLC
11.2 MIMEDX GROUP
11.3 CONVATEC GROUP PLC
11.4 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
11.5 PAUL HARTMANN AG
11.6 MÖLNLYCKE HEALTH CARE AB
11.7 COLOPLAST A/S
11.8 B. BRAUN MELSUNGEN AG
11.9 ORGANOGENESIS HOLDINGS INC.
11.10 MISONIX
11.11 ACELITY (A PART OF 3M)
11.12 ZIMMER BIOMET HOLDINGS INC.
11.13 KERECIS
11.14 MEDLINE INDUSTRIES, INC.
11.15 WELCARE INDUSTRIES S.P.A
11.16 MEDAXIS AG
11.17 PULSECARE MEDICAL
11.18 AROBELLA MEDICAL, LLC
11.19 ADVANCIS MEDICAL
11.20 RLS GLOBAL AB
11.21 MIL LABORATORIES PVT. LTD.

*Business overview, Products offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.